Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.24M | -8.88M | -10.46M | -4.46M | -4.71M |
| Total Depreciation and Amortization | 16.00K | -137.10K | 67.50K | 67.90K | 19.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.12M | 2.42M | 3.68M | 589.80K | 708.00K |
| Change in Net Operating Assets | -1.18M | 72.90K | 1.88M | -156.10K | -749.00K |
| Cash from Operations | -7.29M | -6.53M | -4.83M | -3.95M | -4.73M |
| Capital Expenditure | -6.00K | -900.00 | -5.10K | -- | -1.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -6.00K | -900.00 | -5.10K | -- | -1.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 223.20K | -101.00K | -102.00K | -- |
| Issuance of Common Stock | 7.86M | 2.52M | 4.43M | 6.33M | 4.33M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -247.00K | 145.30K | -194.00K | -852.00K | -144.00K |
| Cash from Financing | 7.61M | 2.89M | 3.00M | 3.88M | 4.18M |
| Foreign Exchange rate Adjustments | -24.00K | 386.50K | 178.60K | -418.50K | 117.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 291.00K | -3.26M | -1.65M | -489.30K | -434.00K |